Status:

COMPLETED

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Lead Sponsor:

Genzyme, a Sanofi Company

Collaborating Sponsors:

BioMarin/Genzyme LLC

Conditions:

Mucopolysaccharidosis I

Hurler's Syndrome

Eligibility:

All Genders

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.

Eligibility Criteria

Inclusion

  • Have a documented diagnosis of MPS I confirmed by measurable signs and symptoms and deficient α-L-iduronidase activity (\<10% of the lower limit of normal).
  • For a patients receiving Aldurazyme therapy prior to study entry: Have available as baseline data the results of urinary GAG levels and IgG antibody titers collected prior to the patient's first Aldurazyme infusion.
  • Provide signed, written informed consent prior to any protocol-related procedures being performed. Consent of a legally authorized guardian(s) is (are) required for patients under 18 years.

Exclusion

  • Have previously received Aldurazyme without the collection of baseline samples as specified.
  • Have a suspected hypersensitivity to Aldurazyme or a know hypersensitivity to components of infusion solution.
  • Have received a Hematopoietic Stem Cell Transplantation, injection fibroblast therapy, or major organ transplant.
  • Are receiving chronic immunosuppressant therapy.
  • Have a medical condition, serious intercurrent illness, or other extenuating circumstances that may interfere with study compliance including all prescribed evaluations and follow-up activities.
  • Are pregnant or lactating
  • Have received investigational drug within 30 days prior to study enrollment

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2007

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00144768

Start Date

July 1 2004

End Date

May 1 2007

Last Update

May 5 2014

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Childrens Hospital Los Angeles

Los Angles, California, United States, 90027

2

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

3

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States, 53226

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | DecenTrialz